Evidence map›Paper›PMID 33964873›Full record

ArticleBMC gastroenterology2021

Retrieval of lost patients in the system for hepatitis C microelimination: a single-center retrospective study.

Hsu-Heng Yen, Pei-Yuan Su, I-L Ing Liu, Ya-Huei Zeng, Siou-Ping Huang, Yu-Chun Hsu, Po-Ke Hsu, Yang-Yuan Chen

Open access · goldAbstract read
In one paragraph

Article in BMC gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Hsu-Heng Yen *Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, No. 135 Nanhsiao Street, Changhua, Taiwan. 91646@cch.org.tw.
Pei-Yuan Su *Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, No. 135 Nanhsiao Street, Changhua, Taiwan.
I-L Ing LiuDivision of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, No. 135 Nanhsiao Street, Changhua, Taiwan.
Ya-Huei ZengDivision of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, No. 135 Nanhsiao Street, Changhua, Taiwan.
Siou-Ping HuangDivision of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, No. 135 Nanhsiao Street, Changhua, Taiwan.
Yu-Chun HsuDivision of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, No. 135 Nanhsiao Street, Changhua, Taiwan.
Po-Ke HsuDivision of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, No. 135 Nanhsiao Street, Changhua, Taiwan.
Yang-Yuan ChenDivision of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, No. 135 Nanhsiao Street, Changhua, Taiwan. 27716@cch.org.tw.
Changhua Christian Hospital · TWMingDao University · TW

Funding

Changhua Christian Hospital 109-CCH-IRP-008
6 · The paper itself

Abstract

backgroundHepatitis C virus (HCV) is one of the major causes of chronic liver disease, cirrhosis, and liver cancer. Most of the infected people have no clinical symptoms. The current strategy for HCV elimination includes test and treatment. In this study, we aimed to evaluate the campaign for retrieving patients who were lost to follow-up, for subsequent re-evaluation.

methodsFrom January 2020 to October 2020, patients who had prior tests for positive anti-HCV antibody in 2010-2018 in our hospital were enrolled for our patient callback campaign. Patients who had unknown HCV RNA status or no documented successful antiviral therapy history were selected for anti-HCV therapy re-evaluation. To facilitate patient referral in the hospital, we developed an electronic reminding system and called the candidate patients via telephone during the study period.

resultsThrough the hospital electronic system, 3783 patients with positive anti-HCV antibody documentation were identified. Among them, 1446 (38.22%) had tested negative for HCV RNA or had anti-HCV therapy, thereby excluded. Of the 2337 eligible patients, 1472 (62.99%) were successfully contacted and called back during the study period for subsequent HCV RNA testing and therapy. We found that 42.19% of the patients had positive HCV RNA and 88% received subsequent anti-HCV therapy.

conclusionsA significant number of patients with positive HCV serology were lost for HCV confirmatory test or therapy in the hospital. Therefore, this targeted HCV callback approach in the hospital is feasible and effective in achieving microelimination.

Indexed as

Hepatitis CHepatitis C, ChronicAntiviral AgentsHepacivirusHepatitis C AntibodiesHumansLiver CirrhosisRetrospective StudiesAntiviral AgentsHepatitis C Antibodies

Identifiers

PMID33964873
PMCPMC8105932
OpenAlexW3161067825

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.